In vitro study on blocking mTOR signaling pathway in EGFR-TKI resistance NSCLC
Asian Pacific Journal of Tropical Medicine
;
(12): 394-397, 2014.
Article
in English
| WPRIM
| ID: wpr-820698
ABSTRACT
OBJECTIVE@#To investigate the effect and mechanism of inhibitor everolimus on EGFR-TKI resistance NSCLC.@*METHODS@#MTT assay was used to detect proliferation of human non-small cell lung cancer cell line A549. Flow cytometry was used to detect the changes of apoptosis and cycle distribution in each group after 24 h and 48 h. RT-PCR was used to detect the changes of PTEN and 4EBP1 expression levels after 48 h of monotherapy and combination therapy.@*RESULTS@#MTT assay showed that everolimus had dose-dependent inhibition against growth of A549 cells. Flow cytometry showed when everolimus could induce apoptosis and induce G0/G1 phase cell cycle arrest, which was time-dependent (P<0.05). RT-PCR showed everolimus could increase PTEN and 4EBP1 expression.@*CONCLUSIONS@#mTOR inhibitor everolimus has an inhibitory effect on EGFR-TKI resistant NSCLC, which cannot reverse the resistance effect of EGFR-TKI resistant cell line A549. The relationship between EGFR/AKT signaling pathway and the mTOR signaling pathway and the mechanism in non-small cell lung cancer need further study.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pharmacology
/
Phosphoproteins
/
Signal Transduction
/
Gene Expression Regulation, Neoplastic
/
Apoptosis
/
Carcinoma, Non-Small-Cell Lung
/
Sirolimus
/
Cell Line, Tumor
/
Adaptor Proteins, Signal Transducing
/
Cell Proliferation
Limits:
Humans
Language:
English
Journal:
Asian Pacific Journal of Tropical Medicine
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS